ABSTRACT
Purpose To investigate the expression of reactive oxygen species (ROS) and PI3K/AKT signaling pathway associated gene protein p70S6K1, VEGF in prostate cancer and adjacent tissues, and to determine their relationship with micro-vascular density ( MVD) , as well as the relationship between themselves. Methods The expression of ROS was detected by immunofluorescence, and the expression of p70S6K1, VEGF and MVD counting were detected by immunohistochemistry. Results Compared to adjacent tis-sues, the expression of ROS, p70S6K1, VEGF and MVD in PCa were increased considerablely (P<0. 05). In prostate cancer the ex-pression of ROS were positively correlated to the expression of p70S6K1, VEGF protein, and the expression of ROS and p70S6K1, VEGF were positively correlated to the number of MVD. Conclusion (1)The expression level of ROS in prostate cancer tissues was significantly higher than adjacent tissues. (2) The expression of PI3K/AKT pathway associated gene protein p70S6K1, VEGF protein and MVD counting in prostate cancer tissue was higher than the adjacent tissues, suggesting PI3K/AKT signaling pathways may play a role in tumor angiogenesis. (3) The expression of ROS and PI3K/AKT pathway associated gene protein p70S6K1, VEGF and MVD counting in prostate cancer tissues was positively correlated, suggesting that ROS may play a positive regulatory role for the development of prostate cancer by PI3K/AKT signaling pathway.
ABSTRACT
Objective To investigate the predictive value of breast cancer susceptibility gene 1 (BRCA1) and class Ⅲβ-tubulin protein expression in tumor tissue for the efficacy of taxol and cisplatin combined chemotherapy (TP) in stage Ⅲβ/Ⅳ non-small cell lung cancer(NSCLC) patients. Methods A total of 92 stage Ⅲβ/Ⅳ NSCLC patients were recruited with 87 patients evaluated. Bronchoscopy or lung puncture tumor biopsy samples were obtained with BRCA1 and class Ⅲβ-tubulin protein expression examined immunohistochemically before chemotherapy. The patients were randomly assigned to be received 4 to 6 cycles of TP chemotherapy regiments and followed up until death or lost. Response rate (RR) , overall survival (OS) and time to tumor progression (TTP) were assessed. Results Among the 87 evaluated patients, the positive expression rates of BRCA1 and class Ⅲβ-tubulin were 57. 5% (50/87) and 48. 3%(42/87) respectively. There was no significant difference in clinical characteristics among patients with different positive expression rate. According to different expression of BRCA1 and class Ⅲβ-tubulin, the patients were divided into four groups: group A (low expression of both BRCA1 and class 1 p-tubulin) ,group B (high expression of both BRCA1 and class Ⅲβ-tubulin) , group C (high expression of only BRCA1) and group D (high expression of only class Ⅲβ-tubulin). The RR was higher in group A than other three groups (60. 7% , 34. 8% , 9/19 and 6/17 respectively). The OS and TTP were longer in group A than other three groups [OS: (539. 4 ± 17. 6) days, (267. 2 ± 20. 5) days, (325. 6 ± 24. 1) days and (283.7±26.2) days respectively ; TTP: (256. 9 ± 28. 4) days, (143.8±17.6) days, (179. 3 ± 19. 8)days and (152. 6 ±23. 5) days respectively]. There were no significant differences among the other three groups. Conclusions The expression level of BRCA1 and class Ⅲβ-tubulin in tumor tissue is probably a predictor for the efficacy of TP chemotherapy in NSCLC patients. TP chemotherapy is more suitable for the NSCLC patients with lower expression of both BRCA1 and class Ⅲβ-tubulin. Our study may provide a new sight for tailored chemotherapy in NSCLC patients.